Spero Therapeutics is laying off approximately 75 percent of the company’s workforce as part of a restructuring operation in light of the U.S. Food and Drug Administration’s expected rejection of Spero’s New Drug Application (NDA) for bacterial diseases.
AstraZeneca Plc’s drug Lynparza reduced the risk of relapse and death in breast cancer patients with certain mutations in a late-stage trial, the British drugmaker said on June 3.
Convalescent Plasma Flunks Study in Covid-19 Patients with Severe PneumoniaArgentina, Convalescent Plasma, COVID-19 Infections, Covid-19 Pneumonia, COVID-19 Studies, Emergency Use Authorization, FDA, Mortality, R&D, SARS-CoV-2 virus, The New England Journal of Medicine (NEJM), U.S. Health Secretary Alex Azar
A study showed the use of convalescent plasma provided no clinical benefit nor improved mortality in Covid-19 patients with pneumonia.
FDA Approves Flu Treatment for Preventative Use After ExposureApprovals, Clinical Trials, Coronavirus Disease (COVID-19) Pandemic, European Medicines Agency, FDA/Regulatory, First-In-Class, Flu Vaccines, Influenza, R&D, Rolling Review, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), The New England Journal of Medicine (NEJM), Therapeutics
Genentech’s influenza treatment Xofluza (baloxavir marboxil) was granted approval by the U.S. Food and Drug Administration for use in people 12 years and older, making it the first single-dose post-exposure prophylaxis strategy approved by the regulatory agency.
Amylyx Pharmaceuticals Inc. announced the publication of results from the pivotal CENTAUR trial evaluating AMX0035 – an investigational neuroprotective therapy designed to reduce the death and dysfunction of motor neurons – in people with amyotrophic lateral sclerosis (ALS) in the New England Journal of Medicine.
Creative Agency Aims To Slow Coronavirus By Giving Away Plans For Barcode Scanner Fused With UV EmitterBacteria, Barcode Scanners, Coronavirus Disease 2019 (COVID-19), Healthcare Communications Agencies, Marketing & Advertising, Medical Devices, Packaging, Science Magazine, The New England Journal of Medicine (NEJM), UV-C Light Technology, Viruses
A new weapon in the war on coronavirus is on the way. Leading health creative agency The Bloc developed SafeCode, a unique device concept which fuses a barcode scanner with UV-C light technology proven to destroy dangerous viruses and bacteria, and is expected to do the same to SARS-CoV-2, the virus that causes the novel coronavirus (COVID-19).
Takeda Pharmaceutical Company Limited announced further results from the VARSITY study, which demonstrated the superiority of the gut-selective biologic vedolizumab (Entyvio) to the anti-tumor necrosis factor-alpha biologic adalimumab (Humira) in achieving the primary endpoint of clinical remission at week 52 in patients with moderately to severely active ulcerative colitis, were published in The New England Journal of Medicine (NEJM).
Researchers may have found a solution to treating a bone marrow cancer proven to be resistant to several standard therapies.
Blue Cross Blue Shield of Massachusetts’ Alternative Quality Contract slowed the rate of medical spending growth by up to 12 percent while improving patient care over the course of eight years, according to a Harvard Medical School study published in the New England Journal of Medicine.
Boehringer Ingelheim Lands Positive Results in Lung Disease TrialClinical Trials, Connective Tissue, Data, European Medicines Agency, FDA, Idiopathic Pulmonary Fibrosis, merican Thoracic Society (ATS) International Conference, Priority Review Status, R&D, Researchers, Scleroderma, Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD), The New England Journal of Medicine (NEJM)
Boehringer Ingelheim’s SENSCIS Phase III clinical trial met the primary endpoint for nintedanib in patients with SSc-ILD.